SHANGHAI, CHINA, Oct 30, 2025- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the execution of an Amendment to its strategic collaboration agreement with Regeneron Pharmaceuticals, Inc. (“Regeneron”), a leading global biotechnology company. This amendment not only signifies a major upgrade in long-term partnership between the two companies, but also marks the beginning of a new phase of collaboration in TCR-T cell therapy and platform innovation.
The aggregate consideration receivable by the Company under the Amendment, consisting of the MAGE-A4 Product Development Milestone Payments, the DPP Regulatory Milestone Payments, the Option Exercise Fee, the LVMP Milestone Payments. Aggregate consideration under the amendment will not exceed approximately US$50 million.
Under the amended agreement, Regeneron will fund certain development activities performed by JW Therapeutics relating to the MAGE-A4 Product. Regeneron will pay the Company an upfront payment upon execution of the Amendment and a series of one-time, non-refundable milestone payments upon achievement of certain development milestone events as set forth in the Amendment. This cost-sharing mechanism enhances JW Therapeutics’ financial position by reducing capital expenditure while ensuring continued progress on a solid tumor program addressing a huge unmet medical need. JW Therapeutics will retain the right to develop and commercialize this product in the Greater China region.
The Amendment further broadens the collaboration scope to incorporate core technology licensing. Regeneron has been granted non-exclusive global license under JW Therapeutics’ proprietary Drug Product Process, along with an option to license JW Therapeutics’ Lentiviral Vector Manufacturing Process. The above self-developed internal process platform has been validated by a leading global partner, underscoring JW Therapeutics’ process innovation, GMP maturity, and technical excellence.
Under these non-exclusive licensing terms, JW Therapeutics retains full ownership and commercial control of its core technologies while maintaining the flexibility to engage in future partnerships. The collaboration aligns with JW Therapeutics’ broader strategic objective to establish long-term platform value and contribute to the global cell therapy landscape.
Min Liu, Chairman and CEO of JW Therapeutics, said, “This Amendment represents a validation of JW Therapeutics’ technology capabilities and our potential to deliver clinical and commercial innovation in solid tumor. We are honored to deepen our collaboration with Regeneron, accelerate the development of more cell immunotherapy products with breakthrough therapeutic value and look forward to shaping the future of cell therapy together.”
This enhanced collaboration further demonstrates JW Therapeutics’ R&D capabilities, platform value, and global partnership competencies in the cell therapy field, while reinforcing the company's commitment to delivering sustainable long-term value for both patients and shareholders.
About JW Therapeutics
JW Therapeutics (HKEx:2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products. Since its founding in 2016, JW Therapeutics has built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors and autoimmune diseases. JW Therapeutics is committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in China and beyond, and to leading the healthy and standardized development of China’s cell immunotherapy industry. For more information, please visit www.jwtherapeutics.com.
About Regeneron
Regeneron is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Its core business strategy is to maintain a strong foundation in scientific research and drug development using our proprietary technologies, and to build on that foundation with our clinical development, manufacturing, and commercial capabilities. Its objective is to continue to advance as an integrated, multi-product biotechnology company that provides patients and medical professionals with important medicines for preventing and treating human diseases.
Forward-Looking Statements
The forward-looking statements are based on the management's expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described. Significant risks and uncertainties, include those discussed below and more fully described in Hong Kong Exchanges and Clearing Limited (HKEx) reports filed by the Company. Unless otherwise noted, the Company is providing this information as of the date it publicized, and expressly disclaims any duty to update information contained in the issues and relevant information, or provide any explanation. For detailed information, please visit the company website: www.jwtherapeutics.com/en/forward-looking-statements/.